Hot Investor Mandate: Western Europe-Based Financial Institution Seeks Therapeutics & Device Investment Opportunities with Focus in France

13 Feb

A major financial institution based in Western Europe is focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-3 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in France, but will consider opportunities in other areas of Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health.  The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics, including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases.  The firm is open to investing in repurposed drugs.  The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in France, but will consider opportunities elsewhere in Europe: within France the firm is typically a lead investor, but in other regions The firm prefers to be a follow-on investor. The firm focuses on investing in companies which have also received an investment from a VC that the firm is invested in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: